Skip to content

Study · Randomized controlled trial · 2025

6 results

Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.

Malhotra A, Grunstein RR, Azarbarzin A, Sands SA, Dang X, Chakladar S, Dunn JP, Falcon B, Bednarik J

Sleep medicine14 Oct 2025Cited by 9 (Europe PMC)

PMID41135142 (opens in a new tab)PMCIDPMC12723708 (opens in a new tab)DOI10.1016/j.sleep.2025.106853 (opens in a new tab)PepBankPUB-41135142
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and obstructive sleep apnea, tirzepatide improved peripheral apnea-hypopnea index versus baseline, significantly from Week 4.

    In plain wordsIn adults with sleep apnea, tirzepatide improved breathing events during sleep compared with the start, as early as Week 4.

    Peptide
    Tirzepatide
    Outcome
    DecreasePeripheral AHI change from baseline, time course
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The tirzepatide-associated improvements in pAHI were significant vs baseline as early as Week 4.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and obstructive sleep apnea, the tirzepatide difference from placebo in peripheral AHI was not significant until Week 20.

    In plain wordsIn adults with sleep apnea, tirzepatide beat placebo on breathing events during sleep only from Week 20.

    Peptide
    Tirzepatide
    Outcome
    DecreasePeripheral AHI difference from placebo, time to significance
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the estimated treatment difference compared to placebo was not significant until Week 20 for both pAHI and WatchPAT-based SASHB.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and obstructive sleep apnea, the tirzepatide difference from placebo in sleep apnea-specific hypoxic burden was not significant until Week 20.

    In plain wordsIn adults with sleep apnea, tirzepatide beat placebo on low-oxygen burden during sleep only from Week 20.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWatchPAT-based SASHB difference from placebo, time to significance
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the estimated treatment difference compared to placebo was not significant until Week 20 for both pAHI and WatchPAT-based SASHB.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).
  4. 04HumanRandomized controlled trialMechanism

    In two SURMOUNT-OSA studies, the size of the change in AHI was associated with the weight reduction achieved with tirzepatide.

    In plain wordsIn adults with sleep apnea on tirzepatide, bigger improvements in breathing events were linked to more weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAssociation of AHI change with weight reduction
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).
  5. 05HumanRandomized controlled trialMechanism

    In two SURMOUNT-OSA studies, the size of the change in sleep apnea-specific hypoxic burden was associated with the weight reduction achieved with tirzepatide.

    In plain wordsIn adults with sleep apnea on tirzepatide, bigger improvements in low-oxygen burden were linked to more weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAssociation of SASHB change with weight reduction
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 06HumanNot a test of Tirzepatide aloneRandomized controlled trialOther

    In SURMOUNT-OSA Study 1, WatchPAT peripheral AHI and SASHB results were consistent with the polysomnographic findings.

    In plain wordsIn one sleep apnea study, the home-based watch test gave results consistent with the sleep-lab test.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAgreement of WatchPAT measures with polysomnography
    Study

    n: not reported in source

    Comparator
    Polysomnography
    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The results of peripheral AHI (pAHI) and SASHB measurements from WatchPAT 300 in Study 1 were consistent with the polysomnographic (PSG) findings.
    1 context sentence
    Summary · context
    The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05412004

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Eli Lilly and Companyn = 46921 Jun 2022 to 29 Mar 2024

Obstructive Sleep Apnea · Obesity

Trial pageClinicalTrials.govUpdated 30 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.